Poor graft function after allogeneic hematopoietic stem cell transplantation is associated with a severely altered bone marrow endothelial microenvironment, as revealed by CD31 expression: An Egyptian single center experience [0.03%]
同种异基因造血干细胞移植后移植物功能不良与骨髓内皮微环境严重改变相关：来自埃及单中心的经验
Mary Gamal Naguib,Nermin Adel Nabih Abdel-Ghafar,Soha Raouf Youssef Mikhaeil et al.
Mary Gamal Naguib et al.
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is definitive, potential curative therapy for various hematological diseases. Poor graft function (PGF) remains a significant complication, char...
The effect of SGLT2 inhibition on immune cells and transplant rejection/failure: A drug-targeted mendelian randomization study [0.03%]
SGLT2抑制剂对免疫细胞和移植排斥/失败的影响：一种药物靶向孟德尔随机化研究
Hanyu Xiao,Xiang Zeng,Qidan Pang et al.
Hanyu Xiao et al.
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) yield additional cardiorenal benefits beyond glycemic control. Emerging evidence suggests that SGLT2i have potential benefits in organ transplantation, though...
Impact of immunosuppressive therapy on non-melanoma skin cancer after solid organ transplantation: A critical systematic review [0.03%]
器官移植后免疫抑制治疗对非黑色素瘤皮肤癌影响的批判性系统综述
Joseph A Abulail,Sara Abu Husein,Maya Al-Tamimia et al.
Joseph A Abulail et al.
Recent advancements in immunosuppressive therapy have markedly reduced graft rejection rates post-transplantation and improved the life expectancy of solid organ transplant recipients. However, these improved long-term outcomes are accompan...
Influence of tacrolimus concentration-to-dose ratio on CLAD risk in lung transplant recipients [0.03%]
他克莫司浓度与剂量比值对肺移植受者CLAD风险的影响
Quentin Perrier,Léa Liaigre,Christel Saint Raymond et al.
Quentin Perrier et al.
Introduction: Lung transplantation remains a vital treatment for patients with end-stage respiratory diseases, yet chronic lung allograft dysfunction (CLAD) continues to be a major complication. Identifying predictive bio...
Early donor-specific antibodies in pediatric patients with Fontan circulation after heart transplant [0.03%]
Fontan循环心脏移植后儿科患者早期供者特异性抗体产生
Hala K El Mikati,Matthew Najor,Natalie Sinicropi et al.
Hala K El Mikati et al.
Background: De novo donor specific antibodies (DSA) are associated with increased morbidity and mortality in adults after heart transplant (HT). We describe our experience with pediatric patients undergoing HT for Fontan ...
Deliberate omission of complement-dependent cytotoxicity crossmatch in deceased donor kidney transplantation: A single-Centre experience using flow cytometry and Luminex-based antibody screening [0.03%]
采用流式细胞术和Luminex技术进行死体供肾移植中故意省略补体依赖的细胞毒性交叉配型的一项单中心经验研究
Chauhan Rajni,Aseem Kumar Tiwari,Bhardwaj Gunjan et al.
Chauhan Rajni et al.
T-cell receptor-engineered T cells (TCR-e T cells): A novel cellular therapy for hematopoietic malignancies? [0.03%]
基因改造的T细胞受体(TCR)工程T细胞：一种治疗血液系统恶性肿瘤的新细胞疗法？
Kajetan Karaszewski,Wiesław Wiktor Jędrzejczak
Kajetan Karaszewski
Despite the undeniable successes of chimeric antigen receptor T cells in the treatment of numerous hematopoietic malignancies, instances in which this therapy shows limited effectiveness, such as in acute myeloid leukemia (AML), still exist...
Preformed HNA-3a antibodies in renal transplantation: A suggested approach to risk assessment [0.03%]
肾移植中预存的HNA-3a抗体：风险评估建议方法
Rishabh Suvarna,Ankit Gupta,Adrienne Seitz et al.
Rishabh Suvarna et al.
Patients presenting with a homozygous human neutrophil antigen-3b (HNA-3b)/3b genotype are at risk of HNA-3a alloimmunisation, generating anti-HNA-3a antibodies, which are known to cause severe transfusion-related acute lung injury (TRALI)....
Anti-lymphocyte globulin versus anti-thymocyte globulin in kidney transplant patients with preformed donor specific antibodies [0.03%]
抗淋巴细胞免疫球蛋白与抗胸腺细胞免疫球蛋白对预存供者特异性抗体肾移植患者的效果比较
Nassim Kamar,Nicolas Congy-Jolivet,Sofiane Salhi et al.
Nassim Kamar et al.
State-of-the-art immunosuppressant therapies recommend the use of induction therapy after kidney transplantation. Anti-interleukin-2 receptor antibody (basiliximab) is used for low-risk patients whereas polyclonal anti-lymphocyte sera (ALS)...
Prolonged cold ischemia promote the progression of chronic allograft nephropathy by chemokine C-C ligand 2 induced macrophage recruitment [0.03%]
补体C-C配体2诱导的巨噬细胞募集促进长期低温缺血致慢性移植物肾病进展
Shaohua Wu,Xiao-Ling Liang,Xunfeng Zou
Shaohua Wu
Background: Prolonged cold ischemia (pCI) is a well-established risk factor for both acute kidney injury and chronic allograft nephropathy (CAN). The chemokine C-C motif ligand 2 (CCL2) plays a pivotal role in sustaining ...